The DOI matches its Crossref record; 180 of the 180 references it cites were found in a registry or an index.
Assessment of Enzyme Inhibition: A Review with Examples from the Development of Monoamine Oxidase and Cholinesterase Inhibitory Drugs
Open accessAbstract
The actions of many drugs involve enzyme inhibition. This is exemplified by the inhibitors of monoamine oxidases (MAO) and the cholinsterases (ChE) that have been used for several pharmacological purposes. This review describes key principles and approaches for the reliable determination of enzyme activities and inhibition as well as some of the methods that are in current use for such studies with these two enzymes. Their applicability and potential pitfalls arising from their inappropriate use are discussed. Since inhibitor potency is frequently assessed in terms of the quantity necessary to give 50% inhibition (the IC50 value), the relationships between this and the mode of inhibition is also considered, in terms of the misleading information that it may provide. Incorporation of more than one functionality into the same molecule to give a multi-target-directed ligands (MTDLs) requires careful assessment to ensure that the specific target effects are not significantly altered and that the kinetic behavior remains as favourable with the MTDL as it does with the individual components. Such factors will be considered in terms of recently developed MTDLs that combine MAO and ChE inhibitory functions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new and rapid colorimetric determination of acetylcholinesterase activity
Ellman, G. L., Courtney, K. D., Andres, V., & Featherstone, R. M. (1961) · Biochemical Pharmacology · doi:10.1016/0006-2952(61)90145-9 · Cited by 27,126
International Journal of Molecular Sciences
(2024) · International Journal of Molecular Sciences · doi:10.3390/ijms · Cited by 10,111
Hopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305
Sussman, J. L., Harel, M., Frolow, F., Oefner, C., Goldman, A., Toker, L., & Silman, I. (1991) · Science · doi:10.1126/science.1678899 · Cited by 2,707
Acetylcholinesterase Inhibitors: Pharmacology and Toxicology
Colovic, M. B., Krstic, D. Z., Lazarevic-Pasti, T. D., Bondzic, A. M., & Vasic, V. M. (2013) · Current Neuropharmacology · doi:10.2174/1570159x11311030006 · Cited by 2,611
Cholinesterase inhibitors for Alzheimer's disease
Birks, J. S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005593 · Cited by 1,906
Esters of Methanesulfonic Acid as Irreversible Inhibitors of Acetylcholinesterase
Kitz, R., & Wilson, I. B. (1962) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)50153-8 · Cited by 1,519
Acetylcholinesterase — new roles for an old actor
Soreq, H., & Seidman, S. (2001) · Nature Reviews Neuroscience · doi:10.1038/35067589 · Cited by 1,390
The therapeutic potential of monoamine oxidase inhibitors
Youdim, M. B. H., Edmondson, D., & Tipton, K. F. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1883 · Cited by 1,363
Self-citationMONOAMINE OXIDASE: From Genes to Behavior
Shih, J. C., Chen, K., & Ridd, M. J. (1999) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.22.1.197 · Cited by 1,206
Copeland, R. A. (2005) · PubMed · Cited by 1,092
A Comparison of Estimates of Michaelis-Menten Kinetic Constants from Various Linear Transformations
Dowd, J. E., & Riggs, D. S. (1965) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)45254-9 · Cited by 1,046
Fonnum, F. (1969) · Biochemical Journal · doi:10.1042/bj1150465 · Cited by 1,035
Page, M. I., & Jencks, W. P. (1971) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.68.8.1678 · Cited by 1,014
Mechanism of action of organophosphorus and carbamate insecticides.
Fukuto, T. R. (1990) · Environmental Health Perspectives · doi:10.1289/ehp.9087245 · Cited by 1,003
Neurobiology of butyrylcholinesterase
Darvesh, S., Hopkins, D. A., & Geula, C. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1035 · Cited by 891
Acetylcholine beyond neurons: the non‐neuronal cholinergic system in humans
Wessler, I., & Kirkpatrick, C. J. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.185 · Cited by 855
Crystal Structure of Human Butyrylcholinesterase and of Its Complexes with Substrate and Products
Nicolet, Y., Lockridge, O., Masson, P., Fontecilla-Camps, J. C., & Nachon, F. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210241200 · Cited by 840
Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors
Morrison, J. F. (1969) · Biochimica et Biophysica Acta (BBA) - Enzymology · doi:10.1016/0005-2744(69)90420-3 · Cited by 814
Greig, N. H., Utsuki, T., Ingram, D. K., Wang, Y., Pepeu, G., Scali, C., Yu, Q.-S., Mamczarz, J., Holloway, H. W., Giordano, T., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508575102 · Cited by 734
Bach, A. W., Lan, N. C., Johnson, D. L., Abell, C. W., Bembenek, M. E., Kwan, S. W., Seeburg, P. H., & Shih, J. C. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.13.4934 · Cited by 723
Targeting acetylcholinesterase and butyrylcholinesterase in dementia
Lane, R. M., Potkin, S. G., & Enz, A. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705005833 · Cited by 654
Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders
Binda, C., Newton-Vinson, P., Hubálek, F., Edmondson, D. E., & Mattevi, A. (2002) · Nature Structural Biology · doi:10.1038/nsb732 · Cited by 644
Binda, C., Wang, J., Pisani, L., Caccia, C., Carotti, A., Salvati, P., Edmondson, D. E., & Mattevi, A. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070677y · Cited by 607
Meyer, J. H., Ginovart, N., Boovariwala, A., Sagrati, S., Hussey, D., Garcia, A., Young, T., Praschak-Rieder, N., Wilson, A. A., & Houle, S. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.11.1209 · Cited by 585
Comparison of butyrylcholinesterase and acetylcholinesterase
Chatonnet, A., & Lockridge, O. (1989) · Biochemical Journal · doi:10.1042/bj2600625 · Cited by 549
Improved determination of acetylcholinesterase activity in human whole blood
Worek, F., Mast, U., Kiderlen, D., Diepold, C., & Eyer, P. (1999) · Clinica Chimica Acta · doi:10.1016/s0009-8981(99)00144-8 · Cited by 543
A review on coumarins as acetylcholinesterase inhibitors for Alzheimer’s disease
Anand, P., Singh, B., & Singh, N. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.12.042 · Cited by 527
European Archives of Psychiatry and Clinical Neuroscience
(2013) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/406.1433-8491 · Cited by 507
Distinct Monoamine Oxidase A and B Populations in Primate Brain
Westlund, K. N., Denney, R. M., Kochersperger, L. M., Rose, R. M., & Abell, C. W. (1985) · Science · doi:10.1126/science.3875898 · Cited by 504
Molar absorption coefficients for the reduced Ellman reagent: reassessment
Eyer, P., Worek, F., Kiderlen, D., Sinko, G., Stuglin, A., Simeon-Rudolf, V., & Reiner, E. (2003) · Analytical Biochemistry · doi:10.1016/s0003-2697(02)00506-7 · Cited by 504
The International Journal of Neuropsychopharmacology
Lerer, B., Frazer, A., Stahl, S., Farde, L., & Lesch, P. (1998) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145798009018 · Cited by 501
European Journal of Organic Chemistry
(2006) · European Journal of Organic Chemistry · doi:10.1002/(issn)1099-0690 · Cited by 499
Structural insights into ligand interactions at the acetylcholinesterase peripheral anionic site
Bourne, Y. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg005 · Cited by 488
Aldridge, W. N. (1950) · Biochemical Journal · doi:10.1042/bj0460451 · Cited by 476
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease
Bastide, M. F., Meissner, W. G., Picconi, B., Fasano, S., Fernagut, P.-O., Feyder, M., Francardo, V., Alcacer, C., Ding, Y., Brambilla, R., et al. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.07.002 · Cited by 475
New Acetylcholinesterase Inhibitors for Alzheimer's Disease
Mehta, M., Adem, A., & Sabbagh, M. (2012) · International Journal of Alzheimer's Disease · doi:10.1155/2012/728983 · Cited by 436
Weissbach, H., Smith, T. E., Daly, J. W., Witkop, B., & Udenfriend, S. (1960) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)69497-9 · Cited by 409
Cellular and Molecular Neurobiology
(2001) · Elsevier eBooks · doi:10.1016/c2009-0-02243-0 · Cited by 357
Cholinesterases: Roles in the Brain During Health and Disease
Ballard, C., Greig, N., Guillozet-Bongaarts, A., Enz, A., & Darvesh, S. (2005) · Current Alzheimer Research · doi:10.2174/1567205054367838 · Cited by 350
Saura, J., Kettler, R., Da Prada, M., & Richards, J. (1992) · The Journal of Neuroscience · doi:10.1523/jneurosci.12-05-01977.1992 · Cited by 337
Reck, F., Zhou, F., Girardot, M., Kern, G., Eyermann, C. J., Hales, N. J., Ramsay, R. R., & Gravestock, M. B. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0400810 · Cited by 332
Self-citationBar-On, P., Millard, C. B., Harel, M., Dvir, H., Enz, A., Sussman, J. L., & Silman, I. (2002) · Biochemistry · doi:10.1021/bi020016x · Cited by 328
Johnson, G., & Moore, S. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206775193127 · Cited by 321
Arendt, T., Brückner, M. K., Lange, M., & Bigl, V. (1992) · Neurochemistry International · doi:10.1016/0197-0186(92)90189-x · Cited by 314
The graphical determination of Km and Ki
Dixon, M. (1972) · Biochemical Journal · doi:10.1042/bj1290197 · Cited by 295
International review of neurobiology
Barron, K. D. (1969) · Electroencephalography and Clinical Neurophysiology · doi:10.1016/0013-4694(69)90139-4 · Cited by 293
Monoaminergic neuropathology in Alzheimer’s disease
Šimić, G., Babić Leko, M., Wray, S., Harrington, C. R., Delalle, I., Jovanov-Milošević, N., Bažadona, D., Buée, L., de Silva, R., Di Giovanni, G., et al. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.04.001 · Cited by 289
Binda, C., Valente, S., Romanenghi, M., Pilotto, S., Cirilli, R., Karytinos, A., Ciossani, G., Botrugno, O. A., Forneris, F., Tardugno, M., et al. (2010) · Journal of the American Chemical Society · doi:10.1021/ja101557k · Cited by 284
The Origin of the Molecular Diversity and Functional Anchoring of Cholinesterases
Massoulié, J. (2002) · Neurosignals · doi:10.1159/000065054 · Cited by 281
Ramsay, R. R., Dunford, C., & Gillman, P. K. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707430 · Cited by 276
Self-citationHistory and New Developments of Assays for Cholinesterase Activity and Inhibition
Miao, Y., He, N., & Zhu, J.-J. (2010) · Chemical Reviews · doi:10.1021/cr900214c · Cited by 267
Acetylcholinesterase: How is structure related to function?
Silman, I., & Sussman, J. L. (2008) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2008.05.035 · Cited by 263
Amyloid–cholinesterase interactions: Implications for Alzheimer’s disease
Inestrosa, N. C., Dinamarca, M. C., & Alvarez, A. (2008) · The FEBS Journal · doi:10.1111/j.1742-4658.2007.06238.x · Cited by 261
Finberg, J. P. M. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.02.010 · Cited by 257
Radical Ideas about Monoamine Oxidase
Silverman, R. B. (1995) · Accounts of Chemical Research · doi:10.1021/ar00056a003 · Cited by 251
Perrier, A. L., Massoulié, J., & Krejci, E. (2002) · Neuron · doi:10.1016/s0896-6273(01)00584-0 · Cited by 248
Inhibitors of Acetylcholinesterase and Butyrylcholinesterase Meet Immunity
Pohanka, M. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15069809 · Cited by 245
Yang, G., Wang, Y., Tian, J., & Liu, J.-P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074916 · Cited by 241
Research and Development of Donepezil Hydrochloride, a New Type of Acetylcholinesterase Inhibitor
Sugimoto, H., Ogura, H., Arai, Y., Iimura, Y., & Yamanishi, Y. (2002) · Japanese Journal of Pharmacology · doi:10.1254/jjp.89.7 · Cited by 240
A phase II trial of huperzine A in mild to moderate Alzheimer disease
Rafii, M. S., Walsh, S., Little, J. T., Behan, K., Reynolds, B., Ward, C., Jin, S., Thomas, R., Aisen, P. S., & Study, F. T. A. D. C. (2011) · Neurology · doi:10.1212/wnl.0b013e318216eb7b · Cited by 240
Moclobemide: Therapeutic Use and Clinical Studies
Bonnet, U. (2003) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2003.tb00245.x · Cited by 227
Isoniazid and Iproniazid: Activation of Metabolites to Toxic Intermediates in Man and Rat
Nelson, S. D., Mitchell, J. R., Timbrell, J. A., Snodgrass, W. R., & Corcoran, G. B. (1976) · Science · doi:10.1126/science.7838 · Cited by 226
Avigdor Shafferman, C., Velan, B., Ordentlich, A., Kronman, C., Grosfeld, H., Leitner, M., Flashner, Y., Cohen, S., Barak, D., & Ariel, N. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05439.x · Cited by 222
Bolea, I., Juárez-Jiménez, J., de los Rı́os, C., Chioua, M., Pouplana, R., Luque, F. J., Unzeta, M., Marco-Contelles, J., & Samadi, A. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200853t · Cited by 219
Multifunctional compounds: Smart molecules for multifactorial diseases
Bansal, Y., & Silakari, O. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.01.060 · Cited by 212
Structural insights into the mechanism of amine oxidation by monoamine oxidases A and B
Edmondson, D. E., Binda, C., & Mattevi, A. (2007) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2007.05.006 · Cited by 203
Structure of Rat Monoamine Oxidase A and Its Specific Recognitions for Substrates and Inhibitors
Ma, J., Yoshimura, M., Yamashita, E., Nakagawa, A., Ito, A., & Tsukihara, T. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.02.032 · Cited by 200
Pohanka, M., Hrabinova, M., Kuca, K., & Simonato, J.-P. (2011) · International Journal of Molecular Sciences · doi:10.3390/ijms12042631 · Cited by 190
Ramírez, D., & Caballero, J. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17040525 · Cited by 183
Ismaili, L., Refouvelet, B., Benchekroun, M., Brogi, S., Brindisi, M., Gemma, S., Campiani, G., Filipic, S., Agbaba, D., Esteban, G., et al. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.12.003 · Cited by 178
Saura, J., Bleuel, Z., Ulrich, J., Mendelowitsch, A., Chen, K., Shih, J. C., Malherbe, P., Da Prada, M., & Richards, J. G. (1996) · Neuroscience · doi:10.1016/s0306-4522(96)83013-2 · Cited by 168
Termination and beyond: acetylcholinesterase as a modulator of synaptic transmission
Zimmerman, G., & Soreq, H. (2006) · Cell and Tissue Research · doi:10.1007/s00441-006-0239-8 · Cited by 165
Distribution of butyrylcholinesterase in the human amygdala and hippocampal formation
Darvesh, S., Grantham, D. L., & Hopkins, D. A. (1998) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(19980413)393:3<374::aid-cne8>3.0.co;2-z · Cited by 164
De Deurwaerdère, P., & Di Giovanni, G. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.03.004 · Cited by 163
Monoamine oxidase A and repressor R1 are involved in apoptotic signaling pathway
Ou, X.-M., Chen, K., & Shih, J. C. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601515103 · Cited by 160
Monoamine oxidase inhibitors and the cheese effect
Anderson, M. C. M., Hasan, F., McCrodden, J. M., & Tipton, K. F. (1993) · Neurochemical Research · doi:10.1007/bf00978365 · Cited by 160
Self-citationDarvesh, S., Darvesh, K. V., McDonald, R. S., Mataija, D., Walsh, R., Mothana, S., Lockridge, O., & Martin, E. V. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8002075 · Cited by 159
Xie, S.-S., Wang, X., Jiang, N., Yu, W., Wang, K. D. G., Lan, J.-S., Li, Z.-R., & Kong, L.-Y. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.03.040 · Cited by 158
Multi-Target Directed Donepezil-Like Ligands for Alzheimer's Disease
Unzeta, M., Esteban, G., Bolea, I., Fogel, W. A., Ramsay, R. R., Youdim, M. B. H., Tipton, K. F., & Marco, J. L. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00205 · Cited by 156
Self-citationWeinreb, O., Amit, T., Bar‐Am, O., & Youdim, M. B. H. (2012) · Current Drug Targets · doi:10.2174/138945012799499794 · Cited by 154
Bartolucci, C., Perola, E., Pilger, C., Fels, G., & Lamba, D. (2000) · Proteins Structure Function and Bioinformatics · Cited by 152
Bautista‐Aguilera, Ó. M., Esteban, G., Bolea, I., Nikolic, K. M., Agbaba, D., Moraleda, I., Iriepa, I., Samadi, A., Soriano, E., Unzeta, M., et al. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.12.028 · Cited by 147
Slow recovery of human brain MAO B after L‐Deprenyl (Selegeline) withdrawal
Fowler, J. S., Volkow, N. D., Logan, J., Wang, G., Gregor, R. R. M., Schlyer, D. J., Wolf, A. P., Pappas, N. R., Alexoff, D. L., Shea, C. E., et al. (1994) · Synapse · doi:10.1002/syn.890180203 · Cited by 147
Behavioral outcomes of monoamine oxidase deficiency: preclinical and clinical evidence
Bortolato, M., & Shih, J. C. (2011) · International review of neurobiology · doi:10.1016/b978-0-12-386467-3.00002-9 · Cited by 144
Limitation of the Ellman method: Cholinesterase activity measurement in the presence of oximes
Šinko, G., Čalić, M., Bosak, A., & Kovarik, Z. (2007) · Analytical Biochemistry · doi:10.1016/j.ab.2007.07.023 · Cited by 140
Kaasinen, V., Någren, K., Järvenpää, T., Roivainen, A., Yu, M., Oikonen, V., Kurki, T. J. I., & Rinne, J. O. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200212000-00012 · Cited by 139
Joubert, J., Foka, G. B., Repsold, B. P., Oliver, D. W., Kapp, E., & Malan, S. F. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.09.041 · Cited by 128
Guzmán-Ramos, K., Moreno-Castilla, P., Castro-Cruz, M., McGaugh, J. L., Martínez-Coria, H., LaFerla, F. M., & Bermúdez-Rattoni, F. (2012) · Learning & Memory · doi:10.1101/lm.026070.112 · Cited by 127
Weinstock, M., Bejar, C., Wang, R.-H., Poltyrev, T., Gross, A., Finberg, J. P. M., & Youdim, M. B. H. (2000) · Springer eBooks · doi:10.1007/978-3-7091-6301-6_10 · Cited by 124
Selective inhibitors of monoamine oxidase type B and the “cheese effect”
Finberg, J. P. M., & Gillman, P. K. (2011) · International review of neurobiology · doi:10.1016/b978-0-12-386467-3.00009-1 · Cited by 123
Fowler, C. J., Mantle, T. J., & Tipton, K. F. (1982) · Biochemical Pharmacology · doi:10.1016/0006-2952(82)90575-5 · Cited by 116
Self-citationNeuropathy target esterase (NTE): overview and future
Richardson, R. J., Hein, N. D., Wijeyesakere, S. J., Fink, J. K., & Махаева, Г. Ф. (2012) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2012.10.024 · Cited by 115
Inhibition of Cholinesterases by Tetrahydroaminacrin.
Heilbronn, E., Tyrrell, V., Tufte, T., Terry, W. G., Sjöberg, B., & Toft, J. (1961) · Acta chemica Scandinavica/Acta chemica Scandinavica. B, Organic chemistry and biochemistry/Acta chemica Scandinavica. A, Physical and inorganic chemistry/Acta chemica Scandinavica. Series B. Organic chemistry and biochemistry/Acta chemica Scandinavica. Series A, Physical and inorganic chemistry · doi:10.3891/acta.chem.scand.15-1386 · Cited by 114
Youdim, M. B. H. (2013) · Experimental Neurobiology · doi:10.5607/en.2013.22.1.1 · Cited by 113
Ligand binding properties of acetylcholinesterase determined with fluorescent probes
Mooser, G., & Sigman, D. S. (1974) · Biochemistry · doi:10.1021/bi00708a010 · Cited by 111
Wu, X., Li, L., Shi, W. S., Gong, Q., Li, X., & Ma, H. (2015) · Analytical Chemistry · doi:10.1021/acs.analchem.5b04303 · Cited by 107
Branduardi, D., Gervasio, F. L., Cavalli, A., Recanatini, M., & Parrinello, M. (2005) · Journal of the American Chemical Society · doi:10.1021/ja0512780 · Cited by 106
Farina, R., Pisani, L., Catto, M., Nicolotti, O., Gadaleta, D., Denora, N., Soto‐Otero, R., Méndez‐Álvarez, E., Passos, C. D. S., Muncipinto, G., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00599 · Cited by 100
Tipton, K. F., Armstrong, R. N., Bakker, B. M., Bairoch, A., Cornish-Bowden, A. J., Halling, P. J., Hofmeyr, J. S., Leyh, T. S., Kettner, C., Raushel, F. M., et al. (2014) · Perspectives in Science · doi:10.1016/j.pisc.2014.02.012 · Cited by 98
Self-citationFree energy landscape for the binding process of Huperzine A to acetylcholinesterase
Bai, F., Xu, Y., Chen, J., Liu, Q., Gu, J., Wang, X., Ma, J., Li, H., Onuchic, J. N., & Jiang, H. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1301814110 · Cited by 95
One for All? Hitting Multiple Alzheimer's Disease Targets with One Drug
Hughes, R. E., Nikolic, K. M., & Ramsay, R. R. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00177 · Cited by 94
Self-citationPisani, L., Farina, R., Catto, M., Iacobazzi, R. M., Nicolotti, O., Cellamare, S., Mangiatordi, G. F., Denora, N., Soto‐Otero, R., Siragusa, L., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00562 · Cited by 92
The Butyrylcholinesterase K Variant Confers Structurally Derived Risks for Alzheimer Pathology♦
Podoly, E., Shalev, D. E., Shenhar‐Tsarfaty, S., Bennett, E. R., Assayag, E. B., Wilgus, H., Livnah, O., & Soreq, H. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.004952 · Cited by 90
Xie, S., Lan, J., Wang, X., Wang, Z., Jiang, N., Li, F., Wu, J., Wang, J. Q., & Kong, L. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.02.023 · Cited by 88
Kupershmidt, L., Amit, T., Bar‐Am, O., Youdim, M. B. H., & Weinreb, O. (2012) · Antioxidants and Redox Signaling · doi:10.1089/ars.2011.4279 · Cited by 86
Youdim, M. B. H. (2006) · Current Alzheimer Research · doi:10.2174/156720506779025288 · Cited by 83
Inoue, H., Castagnoli, K., der Schyf, C. V., Mabic, S., Igarashi, K., & Castagnoli, N. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35176-6 · Cited by 82
Nikolic, K. M., Mavridis, L., Djikić, T., Vučićević, J., Agbaba, D. D., Yelekçi, K., & Mitchell, J. B. O. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00265 · Cited by 79
Fowler, J. S., Logan, J., Volkow, N. D., Shumay, E., McCall-Perez, F., Jayne, M. C., Wang, G., Alexoff, D. L., Apelskog-Torres, K., Hubbard, B., et al. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.214 · Cited by 78
Monoaminergic and Histaminergic Strategies and Treatments in Brain Diseases
Giovanni, G. D., Štrac, D. Š., Solé, M., Unzeta, M., Tipton, K. F., Mück‐Šeler, D., Bolea, I., Corte, L., Perković, M. N., Pivac, N., et al. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00541 · Cited by 78
Self-citationASS234, As a New Multi-Target Directed Propargylamine for Alzheimer's Disease Therapy
Marco, J. L., Unzeta, M., Bolea, I., Esteban, G., Ramsay, R. R., Romero, A., Martínez‐Murillo, R., Carreiras, M. C., & Ismaïli, L. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00294 · Cited by 77
Self-citationMetrifonate for Alzheimer's disease
López-Arrieta, J., & Schneider, L. S. S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003155.pub3 · Cited by 76
Polasek, T. M., Elliot, D. J., Somogyi, A. A., Gillam, E. M. J., Lewis, B. C., & Miners, J. O. (2006) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2006.02627.x · Cited by 76
Key Targets for Multi-Target Ligands Designed to Combat Neurodegeneration
Ramsay, R. R., Májeková, M., Medina, M., & Valoti, M. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00375 · Cited by 76
Self-citationBinda, C., Wang, J., Li, M., Hubalek, F., Mattevi, A., & Edmondson, D. E. (2008) · Biochemistry · doi:10.1021/bi8002814 · Cited by 75
Henderson, P. J. F. (1973) · Biochemical Journal · doi:10.1042/bj1350101 · Cited by 75
Nelson, D. L., Herbet, A., Pétillot, Y., et al. (1979) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1979.tb02296.x · Cited by 74
Hroudová, J., Singh, N., Fišar, Z., & Ghosh, K. K. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.03.084 · Cited by 74
Metabolism of Monoamine Oxidase Inhibitors
Baker, G. B., Urichuk, L., McKenna, K. F., & Kennedy, S. H. (1999) · Cellular and Molecular Neurobiology · doi:10.1023/a:1006901900106 · Cited by 73
Isatin, regional distribution in rat brain and tissues
Watkins, P., Clow, A., Glover, V. A. S., Halket, J. M., Przyborowska, A. M., & Sandler, M. (1990) · Neurochemistry International · doi:10.1016/0197-0186(90)90154-l · Cited by 73
Monoamine oxidase: radiotracer chemistry and human studies
Fowler, J. S., Logan, J., Shumay, E., Alia‐Klein, N., Wang, G., & Volkow, N. D. (2015) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.3247 · Cited by 71
The progress in the cholinesterase quantification methods
Holas, O., Musílek, K., Pohanka, M., & Kuča, K. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.729037 · Cited by 70
Grisaru, D., Pick, M., Perry, C., Sklan, E. H., Almog, R., Goldberg, I., Naparstek, E., Lessing, J. B., Soreq, H., & Deutsch, V. R. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.1.27 · Cited by 64
George, S. T., & Balasubramanian, A. S. (1981) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1981.tb06447.x · Cited by 64
Hroch, L., Guest, P. N., Benek, O., Soukup, O., Janočková, J., Doležal, R., Kuča, K., Aitken, L., Smith, T., Gunn‐Moore, F. J., et al. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.12.029 · Cited by 63
Self-citationA bioluminescent assay for monoamine oxidase activity
Valley, M. P., Zhou, W., Hawkins, E. M., Shultz, J. W., Cali, J. J., Worzella, T. J., Bernad, L., Good, T., Good, D., Riss, T., et al. (2006) · Analytical Biochemistry · doi:10.1016/j.ab.2006.09.035 · Cited by 62
AChE and the amyloid precursor protein (APP) – Cross-talk in Alzheimer's disease
Nalivaeva, N. N., & Turner, A. J. (2016) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2016.04.009 · Cited by 62
The Early Toxicology of Physostigmine
Proudfoot, A. T. (2006) · Toxicological Reviews · doi:10.2165/00139709-200625020-00004 · Cited by 61
Bar‐Am, O., Weinreb, O., Amit, T., & Youdim, M. B. H. (2008) · Journal of Molecular Neuroscience · doi:10.1007/s12031-008-9139-6 · Cited by 60
Xie, S., Chen, J., Li, X., Su, T., Wang, Y., Wang, Z., Huang, L., & Li, X. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.04.009 · Cited by 60
Mohamed, L. A., Qosa, H., & Kaddoumi, A. (2015) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00040 · Cited by 58
Esteban, G., Allan, J., Samadi, A., Mattevi, A., Unzeta, M., Marco-Contelles, J., Binda, C., & Ramsay, R. (2014) · Biochimica et Biophysica Acta · doi:10.1016/j.bbapap.2014.03.006 · Cited by 57
Self-citationShaw, F. H., & Bentley, G. (1949) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1949.tb37429.x · Cited by 56
Frieling, H., & Bleich, S. (2006) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-006-0660-8 · Cited by 54
Emre, M., Cummings, J. L., & Lane, R. M. (2007) · Journal of Alzheimer s Disease · doi:10.3233/jad-2007-11412 · Cited by 53
BELOVA, E. (1996) · Experiment · doi:10.1163/2211730x96x00144 · Cited by 53
On the formation and nature of the imidazoline I2 binding site on human monoamine oxidase-B
McDonald, G. R., Olivieri, A., Ramsay, R. R., & Holt, A. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2010.09.001 · Cited by 53
Self-citationYi, H. L., Akao, Y., Maruyama, W., Chen, K., Shih, J. C., & Naoi, M. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03573.x · Cited by 53
Seymour, C. B., Mothersill, C. E., Mooney, R., Moriarty, M. J., & Tipton, K. F. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601361 · Cited by 52
Self-citationCheng, A., Scott, A. L., Ladenheim, B., Chen, K., Ouyang, X., Lathia, J. D., Mughal, M. R., Cadet, J. L., Mattson, M. P., & Shih, J. C. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.2037-10.2010 · Cited by 52
New Findings about Ellman’s Method to Determine Cholinesterase Activity
Komersová, A., Komers, K., & Čegan, A. (2007) · Zeitschrift für Naturforschung C · doi:10.1515/znc-2007-1-225 · Cited by 50
Tipton, K. F., McCrodden, J. M., & Youdim, M. B. H. (1986) · Biochemical Journal · doi:10.1042/bj2400379 · Cited by 45
Self-citationVintém, A. P. B., Price, N. T., Silverman, R. B., & Ramsay, R. R. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.02.061 · Cited by 44
Self-citationCOX inhibitors: a patent review (2011 – 2014)
Consalvi, S., Biava, M., & Poce, G. (2015) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2015.1090973 · Cited by 44
Eptastigmine: Ten Years of Pharmacology, Toxicology, Pharmacokinetic, and Clinical Studies
Braida, D., & Sala, M. (2001) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2001.tb00205.x · Cited by 42
Wang, C. C., Borchert, A., Ugun‐Klusek, A., Tang, L. Y., Lui, W. T., Chu, C. Y., Billett, E. E., Kühn, H., & Ufer, C. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.241422 · Cited by 42
Benek, O., Aitken, L., Hroch, L., Kuča, K., Gunn‐Moore, F. J., & Musílek, K. (2015) · Current Medicinal Chemistry · doi:10.2174/0929867322666150114163051 · Cited by 41
Slotkin, T. A., Seidler, F. J., & Ritchie, J. (1998) · Brain Research Bulletin · doi:10.1016/s0361-9230(98)00111-7 · Cited by 39
Chiuccariello, L., Cooke, R. G., Miler, L., Levitan, R. D., Baker, G. B., Kish, S. J., Kolla, N. J., Rusjan, P., Houle, S., Wilson, A. A., et al. (2015) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv078 · Cited by 38
Santillo, M. F., & Liu, Y. (2015) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2015.07.002 · Cited by 37
Rojas, R. J., Edmondson, D. E., Almos, T., Scott, R. H., & Massari, M. E. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.12.063 · Cited by 37
Huang, G., Zhu, F., Chen, Y., Chen, S., Liu, Z., Li, X., Gan, L., Zhang, L., & Yu, Y. (2016) · Analytical Biochemistry · doi:10.1016/j.ab.2016.06.020 · Cited by 37
Hiremathad, A., Chand, K., Esteves, A. R., Cardoso, S. M., Ramsay, R. R., Chaves, S., Keri, R. S., & Santos, M. A. (2016) · RSC Advances · doi:10.1039/c6ra03455a · Cited by 36
Self-citationThe neuroprotective mechanism of action of the multimodal drug ladostigil
Weinreb, O., Amit, T., Bar‐Am, O., Yogev‐Falach, M., & Youdim, M. B. H. (2008) · Frontiers in bioscience · doi:10.2741/3069 · Cited by 35
Luo, L., Li, Y., Qiang, X., Cao, Z., Xu, R., Xia, Y., Xiao, G., Song, Q., Tan, Z., & Deng, Y. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.02.027 · Cited by 35
Yu, P. H., & Tipton, K. F. (1989) · Biochemical Pharmacology · doi:10.1016/0006-2952(89)90522-4 · Cited by 34
Self-citationThe safety and efficacy of safinamide mesylate for the treatment of Parkinson’s disease
Perez‐Lloret, S., & Rascol, O. (2016) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2016.1150783 · Cited by 34
Salsali, M., Holt, A., & Baker, G. B. (2004) · Cellular and Molecular Neurobiology · doi:10.1023/b:cemn.0000012725.31108.4a · Cited by 33
Ng, H.-L., Chen, S., Chew, E., & Chui, W. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.03.002 · Cited by 33
Borštnar, R., Repič, M., Kržan, M., Mavri, J., & Vianello, R. (2011) · European Journal of Organic Chemistry · doi:10.1002/ejoc.201100873 · Cited by 32
Peng, L., Zhang, G., Zhang, D., Wang, Y., & Zhu, D. (2010) · The Analyst · doi:10.1039/c0an00168f · Cited by 31
Kumar, V., Chadha, N., Tiwari, A. K., Sehgal, N., & Mishra, A. K. (2013) · Medicinal Chemistry Research · doi:10.1007/s00044-013-0704-3 · Cited by 30
The kinetics of phenethylhydrazine oxidation by monoamine oxidase
Tipton, K. F., & Spires, I. P. C. (1971) · Biochemical Journal · doi:10.1042/bj1250521 · Cited by 30
Self-citationLiu, W., Rabinovich, A., Nash, Y., Frenkel, D., Wang, Y., Youdim, M. B. H., & Weinreb, O. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.10.028 · Cited by 30
Tao, L.-X., Huang, X., Chen, Y., Tang, X.-C., & Zhang, H. (2016) · Acta Pharmacologica Sinica · doi:10.1038/aps.2016.78 · Cited by 28
Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. I. Biochemical profile.
Curet, O., Damoiseau, G., Aubin, N., Sontag, N., Rovei, V., & JARREAU, F. ‐. (1996) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12817-6 · Cited by 28
Deurwaerdère, P. D., Binda, C., Corne, R., Leone, C., Valeri, A., Valoti, M., Ramsay, R. R., Fall, Y., & Marco‐Contelles, J. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00377 · Cited by 27
Self-citationButyrylcholinesterase K Variant and Alzheimer’s Disease Risk: A Meta-Analysis
Wang, J. (2015) · Medical Science Monitor · doi:10.12659/msm.892982 · Cited by 26
A link between monoamine oxidase-A and apoptosis in serum deprived human SH-SY5Y neuroblastoma cells
Fitzgerald, J. C., Ufer, C., & Billett, E. E. (2007) · Journal of Neural Transmission · doi:10.1007/s00702-007-0692-x · Cited by 25
Haas, R., Jackson, B. C., Reinhold, B. B., Foster, J. D., & Rosenberry, T. L. (1996) · Biochemical Journal · doi:10.1042/bj3140817 · Cited by 25
An improved approach to steady-state analysis of monoamine oxidases
Ramsay, R. R., Olivieri, A., & Holt, A. (2011) · Journal of Neural Transmission · doi:10.1007/s00702-011-0657-y · Cited by 23
Self-citationPredicting targets of compounds against neurological diseases using cheminformatic methodology
Nikolic, K. M., Mavridis, L., Bautista‐Aguilera, Ó. M., Marco‐Contelles, J., Stark, H., Carreiras, M. C., Rossi, I., Massarelli, P., Agbaba, D. D., Ramsay, R. R., et al. (2014) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-014-9816-1 · Cited by 22
Self-citationMonoamine Oxidase-A Physically Interacts with Presenilin-1(M146V) in the Mouse Cortex
Wei, Z.-L., Gabriel, G. G., Rui, L., Cao, X., Pennington, P. R., Chlan‐Fourney, J., Nazarali, A., Baker, G., & Mousseau, D. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-111241 · Cited by 18
Kinetic behavior and reversible inhibition of monoamine oxidases—enzymes that many want dead
Tipton, K. F., Davey, G. P., & McDonald, A. G. (2011) · International review of neurobiology · doi:10.1016/b978-0-12-386467-3.00003-0 · Cited by 17
Self-citationPennington, P. R., Wei, Z., Rui, L., Doig, J. A., Graham, B., Kuski, K., Gabriel, G. G., & Mousseau, D. D. (2011) · Journal of Neural Transmission · doi:10.1007/s00702-011-0616-7 · Cited by 15
Phenyl valerate esterase activity of human butyrylcholinesterase
Mangas, I., Vilanova, E., & Estévez, J. (2017) · Archives of Toxicology · doi:10.1007/s00204-017-1946-5 · Cited by 14
Berson, A., & Soreq, H. (2010) · Rambam Maimonides Medical Journal · doi:10.5041/rmmj.10014 · Cited by 11
Kinetics of Catalyzed Reactions – Biological
McDonald, A. G., & Tipton, K. F. (2002) · Encyclopedia of Catalysis · doi:10.1002/0471227617.eoc127 · Cited by 8
Self-citationMoradov, D., Finkin-Groner, E., Bejar, C., Sunita, P., Schorer-Apelbaum, D., Barasch, D., Nemirovski, A., Cohen, M., & Weinstock, M. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.01.017 · Cited by 7
Cited by
A perspective on multi‐target drug discovery and design for complex diseases
Ramsay, R. R., Popovic‐Nikolic, M. R., Nikolic, K., Uliassi, E., & Bolognesi, M. L. (2018) · Clinical and Translational Medicine · doi:10.1186/s40169-017-0181-2 · Cited by 718
Self-citationToward Multi-Targeted Platinum and Ruthenium Drugs—A New Paradigm in Cancer Drug Treatment Regimens?
Kenny, R. G., & Marmion, C. J. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00271 · Cited by 636
Progress in Alternative Strategies to Combat Antimicrobial Resistance: Focus on Antibiotics
Murugaiyan, J., Kumar, P. A., Rao, G. S., Iskandar, K., Hawser, S., Hays, J. P., Mohsen, Y., Adukkadukkam, S., Awuah, W. A., Jose, R. A. M., et al. (2022) · Antibiotics · doi:10.3390/antibiotics11020200 · Cited by 567
Structural Insight into Geranylgeranyl Diphosphate Synthase (GGDPS) for Cancer Therapy
Pham, A. C., Holstein, S. A., & Borgstahl, G. E. O. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0358 · Cited by 9
Anaya, K., Sus, N., Gadelha, C., & Frank, J. (2019) · Amino Acids · doi:10.1007/s00726-018-2675-7 · Cited by 5
Metadata
- Authors
- Ramsay, R., & Tipton, K.
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2017-07-15
- Volume
- 22
- Issue
- 7
- Pages
- 1192
- ISSN
- 1420-3049 (ISSN-L)
- OpenAlex
- W2734510265
- Cited by
- 258
- References
- 180
- FWCI
- 12.43
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.